Advertisement

Topics

Biogen and Sobi Company Profile

06:49 EST 19th February 2017 | BioPortfolio

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.


News Articles [544 Associated News Articles listed on BioPortfolio]

European Commission approves transfer of marketing authorisation for Alprolix to Sobi

The European Commission (EC) has approved the transfer of the marketing authorization for Alprolix (eftrenonacog alfa), a recombinant clotting factor therapy developed for the treatment of haemophilia...

Sobi Seeks New CEO Who Is Around Sweden, Europe As Business Grows

Sobi's outgoing US-based CEO says his extended handover will “maintain continuity” as Sweden's rare disease specialist searches for a successor...    

Swedish Orphan Biovitrum AB: Alprolix Obtains Reimbursement across the United Kingdom

Swedish Orphan Biovitrum AB (publ) (Sobi™) (http://www.sobi.com/) (STO:SOBI) today announces that the company's product Alprolix® (eftrenonacog alfa), a recombinant human factor IX Fc-fusion prote...

Sobi - Invitation - Presentation Of Sobi's Q4 And FY 2016 Results

  Life Sciences Jobs   ...

BRIEF-Sobi says CEO Geoffrey McDonough to leave company

STOCKHOLM, Jan 9 (Reuters) - Swedish Orphan Biovitrum AB (Sobi) :

Swedish Orphan Biovitrum AB: Elocta Obtains National Reimbursement in Spain, Now Available in the Five Largest Markets in the EU

Swedish Orphan Biovitrum AB (publ) (Sobi™) (http://www.sobi.com/) (STO:SOBI) today announces that the company's product Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion prote...

BRIEF-Sobi says Alprolix approved for reimbursement in Britain

Sept 26 (Reuters) - Swedish Orphan Biovitrum AB (Publ) (Sobi)

Swedish Orphan Biovitrum AB: Milan Zdravkovic joins Sobi as Senior Vice President, Head of Research & Development

Regulatory News: Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (STO: SOBI) today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research Deve....

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 wh...

Safety and Tolerability of Repeat Courses of IM Alefacept

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experi...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan ("Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalentl...

Companies [30 Associated Companies listed on BioPortfolio]

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Inc.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hema...

More Information about "Biogen and Sobi" on BioPortfolio

We have published hundreds of Biogen and Sobi news stories on BioPortfolio along with dozens of Biogen and Sobi Clinical Trials and PubMed Articles about Biogen and Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen and Sobi Companies in our database. You can also find out about relevant Biogen and Sobi Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record